Drugs / FHA11KRASG12V-TCR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06043713 | Dec 2023 → Jan 2028 expected | metastatic malignant neoplasm | Fred Hutchinson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FHA11KRASG12V-TCR | “This phase I trial studies the side effects and best dose of autologous CD8+ and CD4+ transgenic T cells expressing high affinity KRASG12V mutation-specific T cell receptors...” NCT06043713 ↗1“Patients then receive FHA11KRASG12V-TCR IV on day 0.” NCT06043713 ↗ |
| Action | Deplete | “can kill tumor cells.” NCT06043713 ↗ |
| Modality | Cell therapy | “autologous CD8+ and CD4+ transgenic T cells” NCT06043713 ↗ |
| Route | Intravenous | “Receive FHA11KRASG12V-TCR IV” NCT06043713 ↗ |
| Target | KRAS | “recognize KRAS G12V” NCT06043713 ↗ |